PMID- 28675642
OWN - NLM
STAT- MEDLINE
DCOM- 20180601
LR  - 20211204
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 39
IP  - 9
DP  - 2017 Sep
TI  - Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse 
      association with tumor size in oral squamous cell carcinoma.
PG  - 1876-1887
LID - 10.1002/hed.24854 [doi]
AB  - BACKGROUND: The purpose of this study was to investigate the clinical relevance 
      of phosphorylated ribosomal protein S6 (p-S6), a surrogate marker of mammalian 
      target of rapamycin (mTOR) activation, and p21 in a series of 125 patients with 
      oral squamous cell carcinomas (OSCCs). METHODS: Immunohistochemical analysis was 
      performed to ascertain the phosphorylation status of p-S6 at Ser235/236 and 
      Ser240/244, p21, and p53 protein expression. RESULTS: Expression of 
      phosphorylated S6 protein on either serine 235/236 or serine 240/244 was detected 
      in 83% and 88% tumors, respectively, and both of them were inversely and 
      significantly correlated with the tumor size and local infiltration. Positive p21 
      expression was found in 91.5% of the cases, and was inversely correlated with 
      tumor size. In OSCC, p21 expression correlates with p-S6 levels, a surrogate 
      marker of mTOR activation, independently of p53 status. CONCLUSION: Expression of 
      both p21 and p-S6 was found to inversely associate with tumor size but not 
      survival outcomes in patients with OSCC.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - de Vicente, Juan C
AU  - de Vicente JC
AUID- ORCID: 0000-0002-0991-9465
AD  - Department of Oral and Maxillofacial Surgery, Hospital Universitario Central de 
      Asturias (HUCA), Oviedo, Asturias, Spain.
AD  - Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Hospital 
      Universitario Central de Asturias, Oviedo, Asturias, CIBERONC ISCIII Spain.
FAU - Pena, Ignacio
AU  - Pena I
AD  - Department of Oral and Maxillofacial Surgery, Hospital Universitario Central de 
      Asturias (HUCA), Oviedo, Asturias, Spain.
FAU - Rodrigo, Juan P
AU  - Rodrigo JP
AD  - Department of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), 
      Oviedo, Asturias, Spain.
AD  - Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Hospital 
      Universitario Central de Asturias, Oviedo, Asturias, CIBERONC ISCIII Spain.
FAU - Rodriguez-Santamarta, Tania
AU  - Rodriguez-Santamarta T
AD  - Department of Oral and Maxillofacial Surgery, Hospital Universitario Central de 
      Asturias (HUCA), Oviedo, Asturias, Spain.
FAU - Lequerica-Fernandez, Paloma
AU  - Lequerica-Fernandez P
AD  - Department of Biochemistry, Hospital Universitario Central de Asturias (HUCA), 
      Oviedo, Asturias, Spain.
FAU - Suarez-Fernandez, Laura
AU  - Suarez-Fernandez L
AD  - Department of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), 
      Oviedo, Asturias, Spain.
FAU - Allonca, Eva
AU  - Allonca E
AD  - Department of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), 
      Oviedo, Asturias, Spain.
FAU - Garcia-Pedrero, Juana M
AU  - Garcia-Pedrero JM
AD  - Department of Otolaryngology, Hospital Universitario Central de Asturias (HUCA), 
      Oviedo, Asturias, Spain.
AD  - Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Hospital 
      Universitario Central de Asturias, Oviedo, Asturias, CIBERONC ISCIII Spain.
LA  - eng
PT  - Journal Article
DEP - 20170704
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ribosomal Protein S6)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Biopsy, Needle
MH  - Carcinoma, Squamous Cell/metabolism/mortality/*pathology/surgery
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/metabolism/mortality/*pathology/surgery
MH  - Multivariate Analysis
MH  - Phosphorylation
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Ribosomal Protein S6/*metabolism
MH  - Risk Assessment
MH  - Survival Analysis
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - S6
OT  - immunohistochemistry
OT  - mammalian target of rapamycin (mTOR) activation
OT  - oral squamous cell carcinoma
OT  - p21
EDAT- 2017/07/05 06:00
MHDA- 2018/06/02 06:00
CRDT- 2017/07/05 06:00
PHST- 2016/10/08 00:00 [received]
PHST- 2017/03/01 00:00 [revised]
PHST- 2017/05/01 00:00 [accepted]
PHST- 2017/07/05 06:00 [pubmed]
PHST- 2018/06/02 06:00 [medline]
PHST- 2017/07/05 06:00 [entrez]
AID - 10.1002/hed.24854 [doi]
PST - ppublish
SO  - Head Neck. 2017 Sep;39(9):1876-1887. doi: 10.1002/hed.24854. Epub 2017 Jul 4.